Skip to main content
TipRanks
Go Ultimate75% OFF

Inogen (6IO) Q3 2026 Earnings Report

0 Followers

DE:6IO Q3 2026 EPS Results

Actual EPS
-EUR 0.55
Consensus EPS
-EUR 0.13
Beat/Miss
Missed by -EUR 0.42
One Year Ago EPS
-EUR 0.18

DE:6IO Q3 2026 Revenue Results

Actual Revenue
EUR 69.11M
Expected Revenue
EUR 82.60M
Beat/Miss
Missed by -EUR 13.48M
YoY Revenue Growth
-16.45%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
DE:6IO Upcoming Earnings

Inogen's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:6IO Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-20.47%|
Earnings Call Sentiment|Neutral

The call presented a mixed outlook. Positive developments included a return to U.S. sales growth, higher portable oxygen concentrator volumes, completion of the rental divestiture, substantial planned cost savings, strong liquidity, and investments in new products and adjacent respiratory markets. These were offset by declining total and international revenue, lower gross margin, reduced adjusted profitability, a larger GAAP loss, negative operating cash flow, and guidance for a full-year adjusted net loss. Management expressed confidence in the company's assets and strategy but acknowledged that financial results need to improve.

Company Guidance

Management expects fourth quarter 26 revenue to be in the range of $65 million to $68 million, with continued acceleration of U.S. growth to offset projected softness in international, resulting in full-year 2026 revenue from continuing operations of $298 million to $301 million and full-year 2026 adjusted net loss from continuing operations in the range of $7 million to $8 million. The company expects approximately $20 million in annualized savings by the end of 27 relative to annualized year to date operating expenses, with the first $10 million being completed before the end of 26; together with the divestiture, this is expected to be more than $40 million in annualized operating expense savings compared to the run rate prior to the divestiture. Inogen expects to receive total estimated cash consideration of up to $24.8 million in the first half of 27, and expects the same trend of softer international sales to continue into the fourth quarter.

  • U.S. Sales Returned to Year-Over-Year GrowthU.S. sales were $42.2 million in the third quarter, increasing 3.8% year over year. Growth was driven by distributor demand and new product contributions of approximately 250 basis points, with distributors increasing the number of new patients starting on portable oxygen concentrators.
  • Portable Oxygen Concentrator Unit Volume IncreasedOverall portable oxygen concentrator unit volume increased nearly 6% year over year to 51.9 thousand units and increased 9.5% year to date, reflecting continued demand for Inogen's core products.
  • Rental Business Divestiture CompletedThe U.S. oxygen rental divestiture closed on November 2 for total estimated cash consideration of up to $24.8 million, which the company expects to receive in the first half of 2027. Management said the transaction simplifies the business, improves cash flow and capital efficiency, and allows resources to be directed toward the highest-priority opportunities.
  • Cost Savings Program AnnouncedInogen announced a cost reduction program expected to generate approximately $20 million in annualized savings by the end of 2027 relative to annualized year-to-date operating expenses, with the first $10 million expected to be completed before the end of 2026. Together with the divestiture, the actions are expected to produce more than $40 million in annualized operating expense savings compared with the run rate prior to the divestiture.
  • Operating Expenses DeclinedAdjusted operating expenses were $35.3 million, a decrease of 4.4% compared with the prior-year period and a sequential decline, reflecting cost management efforts. Adjusted SG&A expense was $30.9 million, down 6.5% year over year as cost reductions and operating efficiencies more than offset investments supporting new products and the U.S. sales channel.
  • Cash Position and Debt-Free Balance SheetInogen ended the quarter with $97.7 million in cash, cash equivalents, marketable securities, and restricted cash, with no debt outstanding.
  • Share Repurchases and Increased AuthorizationThe company repurchased 1.8 million common shares for $11.2 million year to date under its share repurchase program. Following the rental divestiture, Inogen increased its existing share repurchase authorization by $15 million, bringing the total authorization to $45 million.
  • International Market Leadership and Expansion OpportunitiesDespite a third-quarter decline, management said Inogen remains a clear market leader in Europe, with significant growth over the past two years. The company is increasingly focused on leveraging that position to expand international opportunities beyond Europe, particularly across Asia Pacific and Latin America.
  • Investment in Clinical Evidence and New ProductsAdjusted R&D expense increased 13.3% year over year to $4.4 million, reflecting investment in clinical evidence generation and new product development to support long-term differentiation and growth.
  • Expansion Into Adjacent Respiratory MarketsInogen is expanding into adjacent respiratory markets, including sleep and airway clearance. Management said Aurora and Voxi are starting to contribute growth and that the broader respiratory portfolio is intended to create new paths to sustainable profitable growth and shareholder value.
  • Strong Liquidity Supports Continued InvestmentManagement said the balance sheet provides flexibility to return capital to shareholders while continuing to invest in growth, and that the company intends to remain disciplined in its approach to capital allocation.

DE:6IO Earnings History

DE:6IO earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)-0.18--0.23――
Nov 05, 20262026 (Q3)-0.13-0.55-0.18-205.00% (-0.37)
Aug 06, 20262026 (Q2)-0.14-0.13-0.136.67% (+0.01)
May 07, 20262026 (Q1)-0.25-0.27-0.22-20.00% (-0.04)
Feb 24, 20262025 (Q4)-0.32-0.23-0.3736.59% (+0.13)
Nov 05, 20252025 (Q3)-0.19-0.18-0.2220.00% (+0.04)
Aug 07, 20252025 (Q2)-0.24-0.13-0.2137.50% (+0.08)
May 07, 20252025 (Q1)-0.40-0.22-0.5659.68% (+0.33)
Feb 25, 20252024 (Q4)-0.54-0.37-1.0264.04% (+0.65)
Nov 07, 20242024 (Q3)-0.44-0.22-1.7687.31% (+1.54)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed